Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1993 Sep;110(1):423–427. doi: 10.1111/j.1476-5381.1993.tb13827.x

Specific inhibition of leukotriene B4 (LTB4)-induced neutrophil emigration by 20-hydroxy LTB4: implications for the regulation of inflammatory responses.

E R Pettipher 1, E D Salter 1, R Breslow 1, L Raycroft 1, H J Showell 1
PMCID: PMC2176035  PMID: 8220903

Abstract

1. The interaction between leukotriene B4 (LTB4) and its metabolite, 20-hydroxy LTB4 in the control of neutrophil emigration was examined in guinea-pig skin. 2. Leukotriene B4 (10-300 ng) elicited a dose-dependent increase in neutrophil infiltration (as measured by myeloperoxidase activity) 4 h after injection into guinea-pig skin. In contrast, 20-hydroxy LTB4 (30-1000 ng) displayed only weak inflammatory activity in this assay. 3. Although 20-hydroxy LTB4 had low agonist activity, this metabolite caused a potent dose-dependent inhibition of responses to LTB4 (100 ng), when administered systemically (ED50 = 1.3 micrograms kg-1, s.c.) without significantly affecting neutrophil infiltration in response to C5a (2 micrograms). Systemic administration of 20-carboxy LTB4 (10 micrograms) did not affect neutrophil accumulation in response to LTB4 or C5a. In addition, neither 15(S)-hydroxy 5(S)-HPETE(10 micrograms) nor lipoxin A4 (10 micrograms) inhibited responses to LTB4. 4. Addition of 20-hydroxy LTB4 (10(-11)-10(-8) M) to human blood prior to isolation of the neutrophils led to concentration-dependent decrease in the number of LTB4 receptors and decreased chemotactic responsiveness to LTB4 without affecting responses to C5a. Incubation of blood with 20-carboxy LTB4 (10(-8) M) did not reduce LTB4 receptor number of chemotactic responsiveness to LTB4. 5. These data indicate that although 20-hydroxy LTB4 is a weak agonist at LTB4 receptors, it can desensitize neutrophils to the effects of LTB4 via down-regulation of the high affinity receptor and thus provides evidence for a mechanism whereby inflammatory responses may be regulated.

Full text

PDF
423

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Björk J., Hedqvist P., Arfors K. E. Increase in vascular permeability induced by leukotriene B4 and the role of polymorphonuclear leukocytes. Inflammation. 1982 Jun;6(2):189–200. doi: 10.1007/BF00916243. [DOI] [PubMed] [Google Scholar]
  2. Borgeat P., Samuelsson B. Transformation of arachidonic acid by rabbit polymorphonuclear leukocytes. Formation of a novel dihydroxyeicosatetraenoic acid. J Biol Chem. 1979 Apr 25;254(8):2643–2646. [PubMed] [Google Scholar]
  3. Brain S., Camp R., Dowd P., Black A. K., Greaves M. The release of leukotriene B4-like material in biologically active amounts from the lesional skin of patients with psoriasis. J Invest Dermatol. 1984 Jul;83(1):70–73. doi: 10.1111/1523-1747.ep12261712. [DOI] [PubMed] [Google Scholar]
  4. Bray M. A., Ford-Hutchinson A. W., Smith M. J. Leukotriene B4: an inflammatory mediator in vivo. Prostaglandins. 1981 Aug;22(2):213–222. doi: 10.1016/0090-6980(81)90036-8. [DOI] [PubMed] [Google Scholar]
  5. Carter G. W., Young P. R., Albert D. H., Bouska J., Dyer R., Bell R. L., Summers J. B., Brooks D. W. 5-lipoxygenase inhibitory activity of zileuton. J Pharmacol Exp Ther. 1991 Mar;256(3):929–937. [PubMed] [Google Scholar]
  6. Clancy R. M., Dahinden C. A., Hugli T. E. Oxidation of leukotrienes at the omega end: demonstration of a receptor for the 20-hydroxy derivative of leukotriene B4 on human neutrophils and implications for the analysis of leukotriene receptors. Proc Natl Acad Sci U S A. 1984 Sep;81(18):5729–5733. doi: 10.1073/pnas.81.18.5729. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Dahlén S. E., Björk J., Hedqvist P., Arfors K. E., Hammarström S., Lindgren J. A., Samuelsson B. Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary venules: in vivo effects with relevance to the acute inflammatory response. Proc Natl Acad Sci U S A. 1981 Jun;78(6):3887–3891. doi: 10.1073/pnas.78.6.3887. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Davidson E. M., Rae S. A., Smith M. J. Leukotriene B4, a mediator of inflammation present in synovial fluid in rheumatoid arthritis. Ann Rheum Dis. 1983 Dec;42(6):677–679. doi: 10.1136/ard.42.6.677. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Ferrante A., Thong Y. H. A rapid one-step procedure for purification of mononuclear and polymorphonuclear leukocytes from human blood using a modification of the Hypaque-Ficoll technique. J Immunol Methods. 1978;24(3-4):389–393. doi: 10.1016/0022-1759(78)90143-6. [DOI] [PubMed] [Google Scholar]
  10. Ford-Hutchinson A. W., Bray M. A., Doig M. V., Shipley M. E., Smith M. J. Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature. 1980 Jul 17;286(5770):264–265. doi: 10.1038/286264a0. [DOI] [PubMed] [Google Scholar]
  11. Ford-Hutchinson A. W., Brunet G., Savard P., Charleson S. Leukotriene B4, polymorphonuclear leukocytes and inflammatory exudates in the rat. Prostaglandins. 1984 Jul;28(1):13–27. doi: 10.1016/0090-6980(84)90110-2. [DOI] [PubMed] [Google Scholar]
  12. Ford-Hutchinson A. W., Rackham A., Zamboni R., Rokach J., Roy S. Comparative biological activities of synthetic leukotriene B4 and its omega-oxidation products. Prostaglandins. 1983 Jan;25(1):29–37. doi: 10.1016/0090-6980(83)90132-6. [DOI] [PubMed] [Google Scholar]
  13. Franke A. E., Andrews G. C., Stimler-Gerard N. P., Gerard C. J., Showell H. J. Human C5a anaphylatoxin: gene synthesis, expression, and recovery of biologically active material from Escherichia coli. Methods Enzymol. 1988;162:653–668. doi: 10.1016/0076-6879(88)62107-0. [DOI] [PubMed] [Google Scholar]
  14. Fretland D. J., Widomski D. L., Shone R. L., Levin S., Gaginella T. S. Effect of the leukotriene B4 receptor antagonist, SC-41930, on experimental allergic encephalomyelitis (EAE) in the guinea pig. Agents Actions. 1991 Sep;34(1-2):172–174. doi: 10.1007/BF01993269. [DOI] [PubMed] [Google Scholar]
  15. Fretland D. J., Widomski D. L., Zemaitis J. M., Walsh R. E., Levin S., Djuric S. W., Shone R. L., Tsai B. S., Gaginella T. S. Inflammation of guinea pig dermis. Effects of leukotriene B4 receptor antagonist, SC-41930. Inflammation. 1990 Dec;14(6):727–739. doi: 10.1007/BF00916375. [DOI] [PubMed] [Google Scholar]
  16. Gimbrone M. A., Jr, Brock A. F., Schafer A. I. Leukotriene B4 stimulates polymorphonuclear leukocyte adhesion to cultured vascular endothelial cells. J Clin Invest. 1984 Oct;74(4):1552–1555. doi: 10.1172/JCI111570. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Goldman D. W., Goetzl E. J. Heterogeneity of human polymorphonuclear leukocyte receptors for leukotriene B4. Identification of a subset of high affinity receptors that transduce the chemotactic response. J Exp Med. 1984 Apr 1;159(4):1027–1041. doi: 10.1084/jem.159.4.1027. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Hansson G., Lindgren J. A., Dahlén S. E., Hedqvist P., Samuelsson B. Identification and biological activity of novel omega-oxidized metabolites of leukotriene B4 from human leukocytes. FEBS Lett. 1981 Jul 20;130(1):107–112. doi: 10.1016/0014-5793(81)80676-x. [DOI] [PubMed] [Google Scholar]
  19. Harvath L., McCall C. E., Bass D. A., McPhail L. C. Inhibition of human neutrophil chemotaxis by the protein kinase inhibitor, 1-(5-isoquinolinesulfonyl) piperazine. J Immunol. 1987 Nov 1;139(9):3055–3061. [PubMed] [Google Scholar]
  20. Higgs G. A., Salmon J. A., Spayne J. A. The inflammatory effects of hydroperoxy and hydroxy acid products of arachidonate lipoxygenase in rabbit skin. Br J Pharmacol. 1981 Oct;74(2):429–433. doi: 10.1111/j.1476-5381.1981.tb09988.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Hoover R. L., Karnovsky M. J., Austen K. F., Corey E. J., Lewis R. A. Leukotriene B4 action on endothelium mediates augmented neutrophil/endothelial adhesion. Proc Natl Acad Sci U S A. 1984 Apr;81(7):2191–2193. doi: 10.1073/pnas.81.7.2191. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Jackson R. H., Morrissey M. M., Sills M. A., Jarvis M. F. Comparison of antagonist and agonist binding to the leukotriene B4 receptor intact human polymorphonuclear neutrophils (PMN). J Pharmacol Exp Ther. 1992 Jul;262(1):80–89. [PubMed] [Google Scholar]
  23. Jesaitis A. J., Bokoch G. M., Tolley J. O., Allen R. A. Lateral segregation of neutrophil chemotactic receptors into actin- and fodrin-rich plasma membrane microdomains depleted in guanyl nucleotide regulatory proteins. J Cell Biol. 1988 Sep;107(3):921–928. doi: 10.1083/jcb.107.3.921. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Kikawa Y., Shigematsu Y., Sudo M. Leukotriene B4 and 20-OH-LTB4 in purulent peritoneal exudates demonstrated by GC-MS. Prostaglandins Leukot Med. 1986 Jul;23(1):85–94. doi: 10.1016/0262-1746(86)90080-6. [DOI] [PubMed] [Google Scholar]
  25. Lawrence R. H., Sorrelli T. C. Decreased polymorphonuclear leucocyte chemotactic response to leukotriene B4 in cystic fibrosis. Clin Exp Immunol. 1992 Aug;89(2):321–324. doi: 10.1111/j.1365-2249.1992.tb06953.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Lefkowith J. B. Essential fatty acid deficiency inhibits the in vivo generation of leukotriene B4 and suppresses levels of resident and elicited leukocytes in acute inflammation. J Immunol. 1988 Jan 1;140(1):228–233. [PubMed] [Google Scholar]
  27. Lin A. H., Ruppel P. L., Gorman R. R. Leukotriene B4 binding to human neutrophils. Prostaglandins. 1984 Dec;28(6):837–849. doi: 10.1016/0090-6980(84)90038-8. [DOI] [PubMed] [Google Scholar]
  28. Lundberg C., Arfors K. E. Polymorphonuclear leukocyte accumulation in inflammatory dermal sites as measured by 51Cr-labeled cells and myeloperoxidase. Inflammation. 1983 Sep;7(3):247–255. doi: 10.1007/BF00917262. [DOI] [PubMed] [Google Scholar]
  29. Marleau S., Fortin C., Poubelle P. E., Borgeat P. In vivo desensitization to leukotriene B4 (LTB4) in the rabbit. Inhibition of LTB4-induced neutropenia during intravenous infusion of LTB4. J Immunol. 1993 Jan 1;150(1):206–213. [PubMed] [Google Scholar]
  30. McMillan R. M., Girodeau J. M., Foster S. J. Selective chiral inhibitors of 5-lipoxygenase with anti-inflammatory activity. Br J Pharmacol. 1990 Nov;101(3):501–503. doi: 10.1111/j.1476-5381.1990.tb14111.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Movat H. Z., Rettl C., Burrowes C. E., Johnston M. G. The in vivo effect of leukotriene B4 on polymorphonuclear leukocytes and the microcirculation. Comparison with activated complement (C5a des Arg) and enhancement by prostaglandin E2. Am J Pathol. 1984 May;115(2):233–244. [PMC free article] [PubMed] [Google Scholar]
  32. O'Flaherty J., Kosfeld S., Nishihira J. Binding and metabolism of leukotriene B4 by neutrophils and their subcellular organelles. J Cell Physiol. 1986 Mar;126(3):359–370. doi: 10.1002/jcp.1041260306. [DOI] [PubMed] [Google Scholar]
  33. Rae S. A., Davidson E. M., Smith M. J. Leukotriene B4, an inflammatory mediator in gout. Lancet. 1982 Nov 20;2(8308):1122–1124. doi: 10.1016/s0140-6736(82)92785-4. [DOI] [PubMed] [Google Scholar]
  34. Salmon J. A., Simmons P. M., Moncada S. The effects of BW755C and other anti-inflammatory drugs on eicosanoid concentrations and leukocyte accumulation in experimentally-induced acute inflammation. J Pharm Pharmacol. 1983 Dec;35(12):808–813. doi: 10.1111/j.2042-7158.1983.tb02901.x. [DOI] [PubMed] [Google Scholar]
  35. Seeger W., Grimminger F., Barden M., Becker G., Lohmeyer J., Heinrich D., Lasch H. G. Omega-oxidized leukotriene B4 detected in the broncho-alveolar lavage fluid of patients with non-cardiogenic pulmonary edema, but not in those with cardiogenic edema. Intensive Care Med. 1991;17(1):1–6. doi: 10.1007/BF01708400. [DOI] [PubMed] [Google Scholar]
  36. Sharon P., Stenson W. F. Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease. Gastroenterology. 1984 Mar;86(3):453–460. [PubMed] [Google Scholar]
  37. Simmons P. M., Salmon J. A., Moncada S. The release of leukotriene B4 during experimental inflammation. Biochem Pharmacol. 1983 Apr 15;32(8):1353–1359. doi: 10.1016/0006-2952(83)90446-x. [DOI] [PubMed] [Google Scholar]
  38. Wedmore C. V., Williams T. J. Control of vascular permeability by polymorphonuclear leukocytes in inflammation. Nature. 1981 Feb 19;289(5799):646–650. doi: 10.1038/289646a0. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES